Isabelle Rosa
Overview
Explore the profile of Isabelle Rosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Degasperi E, Anolli M, Jachs M, Reiberger T, de Ledinghen V, Metivier S, et al.
J Hepatol
. 2025 Jan;
PMID: 39793613
Background & Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for the treatment of compensated chronic HDV infection; however, real-world data in large cohorts of patients with cirrhosis are lacking....
2.
de Ledinghen V, Fougerou-Leurent C, Le Pabic E, Pol S, Alfaiate D, Lacombe K, et al.
JHEP Rep
. 2024 Jul;
6(8):101057.
PMID: 39045338
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate...
3.
Cadranel J, Zougmore H, Efole J, Hanslik B, Causse X, Rosa I, et al.
Eur J Gastroenterol Hepatol
. 2024 Apr;
36(6):735-741.
PMID: 38683191
Background: Data on the management of Hepatitis B-Delta (HB-D) by hepatogastroenterologists (HGs) practicing in nonacademic hospitals or private practices are unknown in France. Objective: We aimed to evaluate the knowledge...
4.
Pariente A, Rosa I, Dharancy S, Hanslik B
Eur J Gastroenterol Hepatol
. 2022 Mar;
34(7):791-800.
PMID: 35352691
Objective: The three-fold objective of this study was to describe the opinions, the population served, and tools used for the management of nonalcoholic fatty liver disease (NAFLD) by French hepato(gastro)enterologists...
5.
Pageaux G, Nzinga C, Ganne N, Samuel D, Dorival C, Zoulim F, et al.
BMC Infect Dis
. 2022 Jan;
22(1):94.
PMID: 35086481
Background: In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis...
6.
Pol S, Luzivika Nzinga C, Dorival C, Zoulim F, Cagnot C, Decaens T, et al.
Aliment Pharmacol Ther
. 2021 Oct;
54(10):1364-1365.
PMID: 34699103
No abstract available.
7.
Ortonne V, Wlassow M, Hezode C, Francois M, Rosa I, Pawlotsky J, et al.
J Clin Virol
. 2021 Jun;
141:104873.
PMID: 34111663
No abstract available.
8.
Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, et al.
Clin Res Hepatol Gastroenterol
. 2021 Apr;
45(5):101713.
PMID: 33930591
Background & Aims: The factors predicting hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B need to be precisely known to improve its detection. We identified pathways and individual predictive factors...
9.
Pariente A, Chazouilleres O, Causse X, Hanslik B, Arpurt J, Henrion J, et al.
Eur J Gastroenterol Hepatol
. 2020 Nov;
33(1S Suppl 1):e197-e205.
PMID: 33252413
Background And Aims: To assess the characteristics, care, treatment response, and outcomes of primary biliary cholangitis (PBC) patients recently followed-up by hepato-gastroenterologists in various French and Belgian healthcare settings. Methods:...
10.
Vallet-Pichard A, Correas J, Dorival C, Zoulim F, Tran A, Bourliere M, et al.
Clin Res Hepatol Gastroenterol
. 2020 Jun;
45(1):101459.
PMID: 32595103
Background: Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on...